Phase
Condition
N/ATreatment
Depemokimab
Placebo
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Participants who are greater than or equal (>=) 40 kilogram (kg) at Screening Visit
Participants who have a documented diagnosis of HES prior to Visit 2.
A history of 2 or more HES flares within the past 12 months prior to Visit 1.
A female participant is eligible to participate if she is not pregnant orbreastfeeding, and one of the following conditions applies: a) woman ofnon-childbearing potential (WONCBP) Or b) woman of childbearing potential (WOCBP)and using a contraceptive method that is highly effective, with a failure rate ofless than (<) 1 percentage (%).
Capable of giving signed informed consent.
Exclusion
Exclusion Criteria:
Participants with HES disease manifestations which in the opinion of theinvestigator may put the participant at unacceptable risk from study participationor confound interpretation of efficacy or safety data.
Participants with chronic or ongoing active infections requiring systemic treatmentor a pre-existing parasitic infestation within 6 months prior to Visit 1.
Participants with a known immunodeficiency (e.g., Human Immunodeficiency Virus [HIV]), other than that explained by the use of OCS or other therapy taken for HES.
Participants with a history of or current lymphoma.
Participants with current malignancy or previous history of cancer in remission forless than 5 years prior to Visit 1. Participants that had localized carcinoma (i.e.,basal or squamous cell) of the skin which was resected for cure will not beexcluded.
Participants with a haematologic malignancy with hypereosinophilia in which HES isnot the primary diagnosis, e.g., chronic myeloid leukaemia, myelodysplasticsyndrome, chronic eosinophilic leukaemia-not otherwise specified.
Cirrhosis or current unstable liver or biliary disease per investigator assessment.
Participants who have severe or clinically significant cardiovascular diseaseuncontrolled with standard treatment.
Participants with current diagnosis of vasculitis.
Hypereosinophila with no clinical symptoms and/or proof of organ dysfunction.
Clinical diagnosis of Eosinophilic granulomatosis with polyangiitis (EGPA).
Participants with an allergy/ intolerance to a monoclonal antibody or biologic, orany of the excipients of the investigational product.
Participants who have a previous documented failure with anti-interleukin (IL)-5/5Rtherapy.
Participants who have received monoclonal antibodies (mAb) within 30 days or 5half-lives, whichever is longer, prior to Visit 1.
Participants who test positive for the FIP1L1-PDGFRα fusion gene.
QT interval corrected for heart rate according to Fridericia's formula (QTcF) ≥450milliseconds (msec) or QTcF ≥480 msec for participants with Bundle Branch Block atScreening Visit 1.
Participants who are not responsive to OCS based on clinical response or bloodeosinophil counts in the opinion of the Investigator.
Participants who are pregnant or breastfeeding.
Study Design
Connect with a study center
GSK Investigational Site
Caba, Buenos Aires C1425BEN
ArgentinaSite Not Available
GSK Investigational Site
Buenos Aires, C1425BEN
ArgentinaActive - Recruiting
GSK Investigational Site
Florida, 1602
ArgentinaActive - Recruiting
GSK Investigational Site
La Plata, B1900
ArgentinaActive - Recruiting
GSK Investigational Site
Mar del Plata, 7600
ArgentinaActive - Recruiting
GSK Investigational Site
Quilmes, 1878
ArgentinaActive - Recruiting
GSK Investigational Site
Canberra, Australian Capital Territory 2606
AustraliaSite Not Available
GSK Investigational Site
Garran, Australian Capital Territory 2606
AustraliaCompleted
GSK Investigational Site
Bruxelles, 1070
BelgiumActive - Recruiting
GSK Investigational Site
Leuven, 3000
BelgiumSite Not Available
GSK Investigational Site
Blumenau, 89030-101
BrazilActive - Recruiting
GSK Investigational Site
Porto Alegre, 90035-903
BrazilActive - Recruiting
GSK Investigational Site
Rio de Janeiro, 21.941-913
BrazilSite Not Available
GSK Investigational Site
Sorocaba, 18040-425
BrazilActive - Recruiting
GSK Investigational Site
Toronto, Ontario M5G 1X5
CanadaSite Not Available
GSK Investigational Site
Beijing, 100730
ChinaActive - Recruiting
GSK Investigational Site
Changsha, 410008
ChinaActive - Recruiting
GSK Investigational Site
Guangzhou, 510515
ChinaActive - Recruiting
GSK Investigational Site
Harbin, 150010
ChinaActive - Recruiting
GSK Investigational Site
Nanchang, 330006
ChinaActive - Recruiting
GSK Investigational Site
Shanghai, 200025
ChinaActive - Recruiting
GSK Investigational Site
Suzhou, 215006
ChinaActive - Recruiting
GSK Investigational Site
Wuhan, 430022
ChinaActive - Recruiting
GSK Investigational Site
Brno, 625 00
CzechiaSite Not Available
GSK Investigational Site
Brno - Bohunice, 625 00
CzechiaActive - Recruiting
GSK Investigational Site
Hradec Kralove, 500 05
CzechiaActive - Recruiting
GSK Investigational Site
Praha, 14059
CzechiaSite Not Available
GSK Investigational Site
Praha 4, 14059
CzechiaActive - Recruiting
GSK Investigational Site
Usti nad Labem, 40113
CzechiaSite Not Available
GSK Investigational Site
Odense, 5000
DenmarkSite Not Available
GSK Investigational Site
Odense C, 5000
DenmarkActive - Recruiting
GSK Investigational Site
Bad Bramstedt, 24576
GermanySite Not Available
GSK Investigational Site
Mannheim, 68167
GermanyActive - Recruiting
GSK Investigational Site
Athens, 10676
GreeceActive - Recruiting
GSK Investigational Site
Patras, 26054
GreeceSite Not Available
GSK Investigational Site
Patras,Achaia, 26504
GreeceSite Not Available
GSK Investigational Site
Rio Patras, 26054
GreeceActive - Recruiting
GSK Investigational Site
Hong Kong,
Hong KongSite Not Available
GSK Investigational Site
Pokfulam,
Hong KongActive - Recruiting
GSK Investigational Site
Shatin,
Hong KongSite Not Available
GSK Investigational Site
Ramat Gan, 52621
IsraelActive - Recruiting
GSK Investigational Site
Ramat-Gan, 52621
IsraelSite Not Available
GSK Investigational Site
Tel Aviv, 64239
IsraelActive - Recruiting
GSK Investigational Site
Milan, Lombardia 20132
ItalySite Not Available
GSK Investigational Site
Bologna, 40138
ItalySite Not Available
GSK Investigational Site
Catania, 95123
ItalyActive - Recruiting
GSK Investigational Site
Milano, 20132
ItalyActive - Recruiting
GSK Investigational Site
Napoli, 80131
ItalyActive - Recruiting
GSK Investigational Site
Novara, 28100
ItalyActive - Recruiting
GSK Investigational Site
Pavia, 27100
ItalySite Not Available
GSK Investigational Site
Roma, 00168
ItalyActive - Recruiting
GSK Investigational Site
Torino, 10154
ItalySite Not Available
GSK Investigational Site
Treviso, 31100
ItalyActive - Recruiting
GSK Investigational Site
Verona, 37134
ItalyActive - Recruiting
GSK Investigational Site
Aomori, 036-8563
JapanActive - Recruiting
GSK Investigational Site
Chiba, 272-8516
JapanActive - Recruiting
GSK Investigational Site
Gifu, 509-6134
JapanActive - Recruiting
GSK Investigational Site
Hyogo, 670-8540
JapanActive - Recruiting
GSK Investigational Site
Kanagawa, 259-1143
JapanActive - Recruiting
GSK Investigational Site
Miyagi, 980-8574
JapanActive - Recruiting
GSK Investigational Site
Tokyo, 142-8666
JapanActive - Recruiting
GSK Investigational Site
Yamanashi, 409-3898
JapanActive - Recruiting
GSK Investigational Site
Chonju, 561-712
Korea, Republic ofSite Not Available
GSK Investigational Site
Gangwon-do, 26426
Korea, Republic ofSite Not Available
GSK Investigational Site
Gwangju, 61469
Korea, Republic ofActive - Recruiting
GSK Investigational Site
Jeonju, 561-712
Korea, Republic ofActive - Recruiting
GSK Investigational Site
Kangwondo, 26426
Korea, Republic ofActive - Recruiting
GSK Investigational Site
Seoul, 110-744
Korea, Republic ofActive - Recruiting
GSK Investigational Site
Suwon Kyunggi-do, 16499
Korea, Republic ofActive - Recruiting
GSK Investigational Site
Suwon-si, Gyeonggi-do, 16499
Korea, Republic ofSite Not Available
GSK Investigational Site
Guadalajara, 44130
MexicoActive - Recruiting
GSK Investigational Site
Monterrey, 64060
MexicoActive - Recruiting
GSK Investigational Site
Veracruz, 94534
MexicoActive - Recruiting
GSK Investigational Site
Lodz, 90-153
PolandActive - Recruiting
GSK Investigational Site
Bucharest, 31281
RomaniaActive - Recruiting
GSK Investigational Site
Cluj-Napoca, 400124
RomaniaActive - Recruiting
GSK Investigational Site
Barcelona, 08036
SpainActive - Recruiting
GSK Investigational Site
Granada, 18014
SpainActive - Recruiting
GSK Investigational Site
Madrid, 28031
SpainActive - Recruiting
GSK Investigational Site
Pozuelo (Madrid), 28223
SpainSite Not Available
GSK Investigational Site
Pozuelo De AlarcOn Madr, 28223
SpainSite Not Available
GSK Investigational Site
Salamanca, 37007
SpainActive - Recruiting
GSK Investigational Site
Valencia, 46026
SpainActive - Recruiting
GSK Investigational Site
Zaragoza, 50009
SpainActive - Recruiting
GSK Investigational Site
Ankara, 6600
TurkeySite Not Available
GSK Investigational Site
Izmir, 35100
TurkeySite Not Available
GSK Investigational Site
Leicester, LE3 9QP
United KingdomActive - Recruiting
GSK Investigational Site
La Jolla, California 920237
United StatesSite Not Available
GSK Investigational Site
San Diego, California 920237
United StatesSite Not Available
GSK Investigational Site
Atlanta, Georgia 30322
United StatesActive - Recruiting
GSK Investigational Site
Boston, Massachusetts 02111
United StatesSite Not Available
GSK Investigational Site
Southfield, Michigan 48075
United StatesSite Not Available
GSK Investigational Site
Rochester, Minnesota 55905
United StatesActive - Recruiting
GSK Investigational Site
Manhasset, New York 11030
United StatesActive - Recruiting
GSK Investigational Site
Cincinnati, Ohio 45229
United StatesActive - Recruiting
GSK Investigational Site
Columbus, Ohio 43212
United StatesSite Not Available
GSK Investigational Site
Charleston, South Carolina 29425
United StatesActive - Recruiting
GSK Investigational Site
Nashville, Tennessee 37208
United StatesCompleted
GSK Investigational Site
Salt Lake City, Utah 84132
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.